Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

Morning nasal congestion can signal allergies, sinusitis, dry air, GERD, or structural nasal issues. ENT experts say that ...

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Nasal Polyps - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The Nasal Polyps - Pipeline Insight, 2025 report offers ...

Nasal polyposis involves noncancerous growths in the nasal and sinus linings, closely associated with chronic rhinosinusitis. Patients often experience symptoms like congestion, loss of smell, and ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...

Congestion - that bunged up, stuffy nose ­feeling - is usually a fleeting symptom of a cold which lasts for around a week and ...

Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.

Sanofi and Regeneron Pharmaceuticals said their jointly developed Dupixent anti-inflammatory blockbuster drug achieved primary and secondary goals in a late-stage study for allergic fungal ...